MOSES: Procalcitonin Monitoring Sepsis Study

Sponsor
Brahms AG (Industry)
Overall Status
Completed
CT.gov ID
NCT01523717
Collaborator
(none)
858
13
27
66
2.4

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate the relationship between a procalcitonin decrease over 72 hours and outcome in patients who have severe sepsis or septic shock.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    858 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Procalcitonin Decrease Over 72 Hours and Outcome in Patients With Severe Sepsis or Septic Shock
    Study Start Date :
    Dec 1, 2011
    Actual Primary Completion Date :
    Mar 1, 2014
    Actual Study Completion Date :
    Mar 1, 2014

    Outcome Measures

    Primary Outcome Measures

    1. 28 day all cause mortality [within 28 day safter inlclusion]

      participants will be followed up for 28 days

    Secondary Outcome Measures

    1. all-cause in-hospital mortality [mortality during hospital stay]

      count all death through out stay in the hospital

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Adult patients (i.e. >18 years of age) diagnosed with severe sepsis or septic shock as defined in Appendix 1, who are already in the ICU or come from the ED, other wards or directly from out of hospital

    • Blood sample collection within 12 hours after diagnosis "severe sepsis or septic shock"No prior enrollment into this study

    • Written informed consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of California Davis Health System Sacramento California United States 95817
    2 Northwestern University Chicago Illinois United States 60611
    3 Beth Israel Deaconess Medical Center Boston Massachusetts United States 02215
    4 Saint Vincent Hospital Worcester Massachusetts United States 01608
    5 Detroit Receiving Hospital Detroit Michigan United States 48201
    6 Sinai Grace Hospital Detroit Michigan United States 48201
    7 Henry Ford Health System Detroit Michigan United States 48202
    8 University of Mississippi Medical Center Jackson Mississippi United States 39216
    9 New York Methodist Hospital New York New York United States 11215
    10 Stony Brook University New York New York United States 11794
    11 Carolinas Medical Center Charlotte North Carolina United States 28203
    12 Hospital of the University of Pennsylvania Philadelphia Pennsylvania United States 19104
    13 Vanderbilt University Medical Center Nashville Tennessee United States 37232

    Sponsors and Collaborators

    • Brahms AG

    Investigators

    • Principal Investigator: Nathan Shapiro, MD, Beth Israel Deaconess Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Brahms AG
    ClinicalTrials.gov Identifier:
    NCT01523717
    Other Study ID Numbers:
    • brahms-moses
    First Posted:
    Feb 1, 2012
    Last Update Posted:
    Mar 17, 2015
    Last Verified:
    Mar 1, 2015
    Keywords provided by Brahms AG
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 17, 2015